Knowledge about biologics used for psoriasis (such as ustekinumab, secukinumab, ixekizumab, risankizumab) targeting the IL23/IL17 axis, shows that there is also therapeutical potential of JAK inhibitors associated with receptors for these cytokines. Here, IL17A is linked to psoriasis.